Download presentation
Presentation is loading. Please wait.
1
Metastatic Renal Cell Carcinoma
2
Program Goals
3
Incidence of RCC in the United States
4
Survival
5
Current Treatment
6
Toxicities to Treatment
7
IL-2: Function
8
Challenges in Clinical Outcome With Targeted Drugs
9
Nivolumab Mechanism of Action
10
Nivolumab Monotherapy Phase 2 Study Design
11
Prior Therapy in Metastatic Setting
12
PFS Doses of Nivolumab
13
Objective Responses With Nivolumab
14
Duration of Response By Nivolumab Dose (Responding Patients)
15
Nivolumab Monotherapy Treatment-Related AEs
16
Overall Survival
17
Response According to PD-L1 Status by IHC
18
Nivolumab + Sunitinib or Pazopanib
19
Baseline Patient Characteristics
20
Antitumor Activity (per RECIST 1.1)
21
Grade 3-4 Treatment-Related AEs in ≥ 10% of Patients
22
Nivolumab plus Ipilimumab Mechanism of Action
23
CA209-016 (NCT01472081): Phase I Study Design (N + I cohort)
24
Nivolumab + Ipilimumab Dosing schedule
25
Nivolumab + Ipilimumab Baseline Patient Characteristics
26
MPDL3280A Phase 1a Baseline Demographics RCC Patients in Dose-escalation and Dose-expansion Cohorts
27
Nivolumab + Ipilimumab Antitumor Activity
28
Nivolumab + Ipilimumab Time to Response and DOR
29
Nivolumab + Ipilimumab Treatment-Related AEs
30
Nivolumab Next Steps
32
MPDL3280A Phase 1a Safety Overview (RCC)
33
MPDL3280A Phase 1a Efficacy Summary Investigator Assessed
34
Other Checkpoint Inhibitor Trials to Watch
35
Conclusions
36
Abbreviations
37
Abbreviations (cont)
38
Abbreviations (cont)
39
References
40
References (cont)
41
References (cont)
42
References (cont)
43
References (cont)
44
References (cont)
45
References (cont)
46
References (cont)
47
References (cont)
48
References (cont)
49
References (cont)
50
References (cont)
51
References (cont)
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.